Medical imaging artificial intelligence (AI) specialist Avicenna.AI has inked a deal with Canon Medical Systems Corp. to provide a fully integrated stroke detection AI solution for Canon’s Automation Platform. Under this partnership, Avicenna will provide Canon with its U.S. FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke—intracranial hemorrhage (ICH) and large vessel occlusion (LVO)—from CT-scan imaging. 

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, alerting the radiologist within their existing systems and workflow. 

CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity. 

Toshiki Kato, general manager of healthcare IT at Canon Medical Systems, spoke out about the Avicenna partnership, commenting: “It demonstrates our commitment to providing our customers with AI solutions that help them to improve the quality of care. With its proven ability to help radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care, CINA Head is exactly the kind of innovative solution that we want to offer clinicians.”

Cyril Di Grandi, co-founder and CEO of Avicenna.AI, also lauded the deal, saying: “Our partnership with a medical imaging modality leader like Canon Medical Systems is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond.”